Omnicell (OMCL) Q3 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2024 earnings summary
8 Jul, 2026Executive summary
Q3 2024 revenues were $282–$282.4 million, down 5% year-over-year, with product revenues declining and service revenues increasing, reflecting a challenging environment and timing of the XT Series replacement cycle.
GAAP net income for Q3 2024 was $9 million ($0.19 per diluted share), up from $6 million ($0.12 per diluted share) in Q3 2023; non-GAAP net income was $26 million ($0.56 per diluted share), down from $28 million ($0.62 per diluted share) a year ago.
The company is focused on driving recurring and predictable revenues, outcome-centric innovation, and operational excellence, with Advanced Services as a key growth driver.
Leadership expanded with the appointment of Nnamdi Njoku as COO to lead operational change management and cultural evolution.
Omnicell maintains a strong balance sheet, supporting investments in new products and services for sustainable growth.
Financial highlights
Q3 2024 total revenue: $282–$282.4 million, up $6 million sequentially, down $16–$15 million year-over-year.
Q3 GAAP EPS: $0.19 (up from $0.08 prior quarter, $0.12 year-over-year); non-GAAP EPS: $0.56 (up from $0.51 prior quarter, down from $0.62 year-over-year).
Q3 non-GAAP EBITDA: $39 million, down $1–$2 million sequentially and year-over-year.
Product revenue: $158–$158.4 million (down $30–$30.4 million year-over-year); Service revenue: $124–$124.1 million (up $14–$14.2 million year-over-year).
Non-GAAP gross margin: 44.5%, down 120 bps year-over-year, up 30 bps sequentially.
Cash and equivalents: $570.6–$571 million at quarter end; non-GAAP free cash flow: $9 million.
Outlook and guidance
Full-year 2024 guidance: bookings $800–$875 million, revenue $1.1–$1.11 billion, non-GAAP EBITDA $129–$134 million, non-GAAP EPS $1.65–$1.72.
Q4 2024 guidance: revenue $295–$305 million, product revenue $177–$182 million, service revenue $118–$123 million, non-GAAP EBITDA $40–$45 million, non-GAAP EPS $0.55–$0.62.
Advanced Services revenue expected to reach $239–$242 million in 2024, targeted to comprise 22% of total revenue.
Transitioning to new metrics in 2025: product bookings and annual recurring revenue (ARR).
Latest events from Omnicell
- Q2 2026 revenue rose 7% to $312M, with higher margins and a $14M–$15M tariff refund.OMCL
Q2 2026 - Growth accelerates with new cloud-based products, AI integration, and a focus on recurring revenue.OMCL
Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Titan XT and OmniSphere launch drive a pivotal product cycle and margin-focused strategy.OMCL
Bank of America Global Healthcare Conference 2026 - Q1 2026 saw 15% revenue growth, margin gains, and raised profit guidance.OMCL
Q1 2026 - 2026 meeting seeks approval for director elections, pay, equity plan, officer exculpation, and auditor.OMCL
Proxy filing - Proxy seeks approval on director elections, compensation, equity plan, officer exculpation, and auditor.OMCL
Proxy filing - Q4 and FY 2025 revenues and ARR rose, with Titan XT and OmniSphere driving growth and strong 2026 outlook.OMCL
Q4 2025 - Accelerated innovation and advanced services drive growth, margin expansion, and strategic partnerships.OMCL
2024 Wells Fargo Healthcare Conference - Q2 revenue beat guidance; recurring and Advanced Services growth drove raised 2024 outlook.OMCL
Q2 2024